Structure Therapeutics Inc (GPCR) insider trading

Every open-market stock purchase and sale by Structure Therapeutics Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Xichen Lin (C-suite exec) and 1 other sold $1.2M in the last 90 days.
  • Last insider buy: Ramy Farid (Director), $4.1M, 3 years ago.

Last 12 months: insiders bought $0 (0 buys) and sold $7.8M (9 sales). Last close $36.02 on Sep 24, 2026.

Recent GPCR insider trades

DateInsiderTradeValue
Sep 21, 2026Crespo Blas Coll (C-suite exec)Sold$145K
Sep 21, 2026Crespo Blas Coll (C-suite exec)Bought (not open market)—
Sep 21, 2026Crespo Blas Coll (C-suite exec)Sold (not open market)—
Sep 18, 2026Crespo Blas Coll (C-suite exec)Sold (not open market)$124K
Sep 1, 2026Xichen Lin (C-suite exec)Sold$214K
Sep 1, 2026Xichen Lin (C-suite exec)Sold$59.6K
Sep 1, 2026Xichen Lin (C-suite exec)Sold$4.8K
Sep 1, 2026Xichen Lin (C-suite exec)Sold (not open market)—
Sep 1, 2026Xichen Lin (C-suite exec)Bought (not open market)—
Sep 1, 2026Xichen Lin (C-suite exec)Bought (not open market)—
Aug 18, 2026Xichen Lin (C-suite exec)Sold$160K
Aug 18, 2026Xichen Lin (C-suite exec)Sold$28.1K
Aug 18, 2026Xichen Lin (C-suite exec)Sold$22K
Aug 18, 2026Xichen Lin (C-suite exec)Sold (not open market)—
Aug 18, 2026Xichen Lin (C-suite exec)Bought (not open market)—
Aug 18, 2026Xichen Lin (C-suite exec)Bought (not open market)—
Aug 6, 2026John Joseph Berrios (C-suite exec)Bought (not open market)—
Aug 6, 2026John Joseph Berrios (C-suite exec)Bought (not open market)—
Aug 4, 2026Xichen Lin (C-suite exec)Sold$153K
Aug 4, 2026Xichen Lin (C-suite exec)Sold$42K
Aug 4, 2026Xichen Lin (C-suite exec)Bought (not open market)—
Aug 4, 2026Xichen Lin (C-suite exec)Bought (not open market)—
Aug 4, 2026Xichen Lin (C-suite exec)Sold (not open market)—
Jul 14, 2026Xichen Lin (C-suite exec)Sold$319K
Jul 14, 2026Xichen Lin (C-suite exec)Sold$82.7K

Who's trading GPCR

Get free alerts when an insider at Structure Therapeutics Inc files a new trade →